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Abstract
Background: Hand, foot and mouth disease (HFMD) is a common pediatric illness. Mainly induced by the
Enterovirus 71 and Coxsackievirus A 16 infections, the frequently occurred HFMD outbreaks have become a serious
public health problem in Southeast Asia. Currently,only a few studies have investigated the human immunity to
HFMD in China. In this study, we conducted a cohort study in Guangdong province, China.
Methods: Stored serum samples from children less than 10 years old were analyzed. The levels of EV71 and CA16
specific antibodies before, during and shortly after the 2008 large outbreak of HFMD were evaluated by the
microneutralization test. The geometric mean titer (GMT) was calculated and compared. Statistical significance was
taken as P < 0.05.
Results: The seroprevalence data showed a continuous circulation of EV71 and CA16 in Guangdong province
China in 2007–2009. The low positive rate in 2009 correlated well with the unprecedented outbreak of HFMD in
2010. Age related increase of seroprevalence was identified in 1–3 years old children for EV71 and in 1–5 years old
children for CA16 in Guangdong province. High GMT of EV71 and CA16 antibody titers were also found for these
age groups.
Conclusions: All of the above findings indicated common infections for these age groups. And they should clearly
be at the top of the priority in periodical seroprevalence survey and future vaccination campaign.
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Background
Hand, foot and mouth disease (HFMD) is a common
pediatric illness [1]. It is characterized by 3–4 days of
fever and then the development of vesicles on the pal-
mar and plantar skin, buccal mucosa and tongue [2-4].
This illness as itself is mild and self-limited [5]. While in
some cases, accompanied with other neurological com-
plications, HFMD may also lead to severe outcomes and
even death [6-8]. Children under 10 years old especially
those less than 5 are the most susceptible population for
reasons that are not clearly understood [2,9-11].
The first viral agent identified for HFMD is Coxsackievirus
A 16 (CA16) [12]. Belonging to the picornaviridae fa-
mily, this virus, associated with Enterovirus 71 (EV71),
is responsible for nearly all of the HFMD epidemics in
Southeast Asia [13,14]. In Japan, CA16 was reported to
be a prevalent type, while EV71 recurrent every 3 years
[10,15]. In Singapore, from 2001 to 2008, the predomi-
nant EV strains isolated from HFMD cases were CA16
and EV71 [16,17]. In China, EV71 and CA 16 are also
frequently reported to co-circulate and cause HFMD,
although the major etiologic agent identified from hos-
pitalized cases was EV71 [18,19].
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Many large HFMD outbreaks with severe and fatal
outcomes in Southeast Asia have recently been de-
scribed [4,20]. In Taiwan, the most severe HFMD out-
break occurred in 1998, resulting in 405 severe
neurological cases and 78 deaths [21,22]. In China, the
recent outbreaks of HFMD were initiated from 2007 in
Shandong province. Then a national widespread epi-
demic occurred in 2008, with more than 176,000
reported human cases [23]. Contrary to HFMD out-
breaks in other Asian countries, the epidemics in China
were more lasting [24]. Unprecedented HFMD out-
breaks occurred in the following years. By the end of
2010, a total of 3,419,149 cases and 1384 fatal cases were
reported [25,26]. It is said that the recently occurred
HFMD epidemics have become a serious public health
problem in Southeast Asia, especially in China.
Currently,only a few studies have been conducted to
investigate the human immunity to HFMD in China
[27,28]. The seroepidemiology of EV71 infection before,
during and shortly after the epidemics could pave ways
for prophylactic intervention strategies. In addition, sev-
eral EV71 vaccine candidates are being developed in
mainland China from 2008 [29-31]. And some of them
are at various stages of clinical development [32,33]. To
better establishing the immunization program against
EV71 and CA16 infection, seroepidemiological surveil-
lance is urgently needed. In this study, we conducted a
cohort study in Guangdong province, China. Children
less than 10 years old were enrolled. The levels of EV71
and CA16 specific antibodies in children aged between 1




The material used in this study is stored serum samples
collected from the health children ≤9 years of age who
had participated in seasonal immune status surveillance
at Guangdong Provincial Centre for Disease Control and
Prevention, China, from 2007 to 2009. Survey question-
naire was completed by trained interviewers and included
information on the subject’s age, gender, vaccination his-
tory (over the past year) and presence/absence of illnesses
(over the past year). All children had no sign of disease at
the time of sample collection. The serum samples were
stored at −80°C until testing. For the use of these serum
samples, written informed consents from all participants
(their parents or legal guardians) involved in survey were
obtained. Serum samples from children who reported
fever and vesicular exanthema on their hands, feet,
mouths, or buttocks (distinct clinical presentation of
HFMD) over the past year were excluded in this study
and were classified into seven age groups (1, 2, 3, 4, 5, 6–7
and 8–9 years). Each group has 35–40 samples, except age
group 1, 2 years in 2007(3 in 1 year group, 24 in 2 year
group) and 8–9 years group in 2008 and 2009 (24 and 23
samples respectively). The sex ratios of boys to girls were
1.36:1, 1.43:1, and 1.25:1 respectively. The demographic
profile of the subjects is shown in Table 1. The study was
approved by the ethics committee of the Guangdong
Provincial Center for Disease Control and Prevention, and
was in compliance with the Helsinki Declaration.
Neutralizing antibody assay
The neutralizing antibody (NA) tests were performed as
previously described [34]. To define the EV71 neutralizing
antibody, EV71/Guangdong/EV039/2009 (C4 genotype)
strain was used, which is isolated from a fatal case in
2009. For CA16, CA16 Guangdong/CA010/2009 (A geno-
type) strain was used. All of the neutralizing antibody
assays were run in 96-well microplates. Serum samples
were inactivated at 56°C for 30 minutes before use, diluted
two-fold from 1:8 to 1:1,024, and then incubated at 37°C
for 2 hours with equal volumes of 100 half tissue culture
infective doses (100 TCID50) of EV71 or CA16. After the
incubation period, 1 × 105 cells /ml rhabdomyosarcoma
cell lines (RD) were added to each well. Finally, these
plates were incubated in a 5% CO2 incubator at 37°C for 7
days. And the CPE was observed with an inverted micro-
scope from the fourth day. All the diluted samples were
tested in duplicate. Cell control, serum control and virus
control were included in each plate. Viral back titration
was conducted in each test. The antibody titer of the
sample was defined as the highest dilution that could
inhibit cytopathic effect (CPE) development in 50% of
the virus-infected wells. A titer equal to or greater
than 8 were considered as seropositive.
Table 1 Demographic profile of the subjects in three
years studied
2007 2008 2009
No. samples No. samples No. samples
Age groups (years)
1 3 35 36
2 24 34 35
3 36 39 38
4 40 38 37
5 39 39 39
6-7 40 39 37
8-9 40 24 23
Gender
Male 128 146 136
Female 94 102 109
Total 222 248 245
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Statistical analysis
Statistical analyses were performed with SPSS version
13.0. Differences with an error probability of P < 0.05
were regarded as significant. For categorical data, we
used Chi-square testing and Fisher Exact testing as ap-
propriate. Neutralizing antibody titers of positive serum
samples were log-transformed to calculate the geometric
mean titer (GMT) and 95% confidence intervals (CI).
Kruskal–Wallis test was used for comparison of the
GMT by year and age group. Antibody titers >1:1204
were assigned a value of 1204.
Results
Overall seroprevalence of EV71 and/or CA16
EV71 and CA16 NA are widely identified in the popula-
tion in three years tested (Table 2). The seroprevalence of
NA to EV71 was found to be 44.6% (95% CI 38.0–51.0%),
46.4% (95% CI 40.2–52.6%) and 31.8% (95% CI 26.0–
37.6%) in 2007, 2008 and 2009 respectively. EV71 NA
seroprevalence in 2009 showed an obvious decreased
trend when compared to that of 2007 and 2008 (p < 0.05).
Related to EV71, higher seroprevalence was observed for
CA16 NA in same years except for 2008 (p < 0.05). In
2007, 70.3% (95% CI 64.3–76.3%) individuals were
seropositive for CA16 NA. Seroprevalence in 2008 and
2009 was significantly lower than that of 2007 (p < 0.05),
with similar values ranged between 51.6% (95% CI 45.4–
57.8%) and 47.3% (95% CI 41.0–53.6%).
Of all tested individuals, 32.4% (95% CI 25.8–38.2%) and
29.4% (95% CI 23.3–34.7%) revealed neutralizing anti-
bodies against both viruses in 2007 and 2008 (Table 2).
Then the seroprevalence decreased greatly (p < 0.05),
showing a value of 20.4% (95% CI 15.0–25.0%) in 2009.
No significant gender specific difference in seropreva-
lence was observed for both EV71 and CA16 NA
(Table 2). 40.6% (95% CI: 32. 1 – 49. 4%) of boys tested
EV71 NA seropositive, compared to 50.0% (95% CI: 40.0
– 60.2%) among girls in 2007. While for CA16 NA, the
seroprevalence was 71.9% (95% CI: 64.0–79.6%) and
68.1% (95% CI: 58.7–78.9%) respectively. Values in 2008
were 43.8% (boys, 95% CI: 36.2–52.4%) and 50.0%
(girls, 95% CI: 40.5–60.3%) for EV71 NA, 52.7%
(boys, 95% CI: 45.2–61.2%) and 50.0% (girls, 95% CI:
40.5–60.3%) for CA16 NA. 34. 6% (95% CI 26.4–43.5%)
boys and 50.0% (95% CI 41.2–59.3%) boys showed
neutralizing antibodies to EV71 and CA16 respectively in
2009. The proportion of EV71 /CA16 seropositive girls
was 28.4%/44.0%.
Age-dependent seroprevalence of EV71 and/or CA16
The analysis of the different age groups (n = 35–40)
revealed a general increasing trend for EV71 NA
seroprevalence in all of the three years tested, except
for a slight dip at the age of 2 years group in 2008
and 2009 (Figure 1A). The percentage of EV71 NA
positive individual increased from 0%, 28.6% and
11.1% in the first group (age 1 year group; 2007, 2008
and 2009 respectively) to plateau values no less than
40%, 48.7% and 36.8% among 3 to 9 years old indi-
vidual. No obvious rise or decline was observed for
these age groups.
While for CA16, it showed much higher seropreva-
lence than EV71 in nearly all of the age group in three
years tested except in year 2008. Similar with EV71 NA
seroprevalence, an age related increase of CA16 NA
seropositive individuals was observed (Figure 1B). In
2007, children 2 years old had a seroprevalence of
45.8%, and thereafter reached to at least 61.1% in 3–5
years groups, then this value stated at approximately
85% for those aged 6 or older. Compared to 2007,
the age dependent curves in 2008 and 2009 both
showed significant reduction at 2 years group. CA16
NA seroprevalence declined from 28.6% and 30.5% at
1 year group to 5.8% and 8.5% at 2 year group in
2008 and 2009 respectively. Then these values steady
increased to at least 66.7% for children aged 5 or old
in 2008, and to 59.5% for children aged 4 or old in
2009.
A moderate percentage was obtained when testing
neutralizing antibodies against both EV71 and CA 16
(Figure 1C). Children among 2–3 years old had a value
of 20.0%, and 30.0% at age 4, and then reached at 40.0%
for the subsequent groups in 2007. In 2008 and 2009,
the lowest level of NA seroprevalence for these two vi-
ruses was 2.9% and 0.0% respectively, both were found
at age 2. Thereafter the NA seroprevalence stated at
appoximately 30.0% among 3–9 years children.
Table 2 Overall seroprevalence of EV71 and/or CA16
antibody
No. (%) positive
Year No. tested Enterovirus 71 Coxsackie A16 Co-infection
2007
Male 128 52(40.6) 92(71.9) 39(30.4)
Female 94 47(50.0) 64(68.1) 33(35.1)
Total 222 99(44.6) 156(70.3) 72(32.4)
2008
Male 146 64(43.8) 77(52.7) 43(29.5)
Female 102 51(50.0) 51(50.0) 30(29.4)
Total 248 115(46.4) 128(51.6) 73(29.4)
2009
Male 136 47(34.6) 68(50.0) 31(22.8)
Female 109 31(28.4)) 48(44.0) 19(17.4)
Total 245 78(31.8) 116(47.3) 50(20.4)
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Geometric mean titer distribution of EV71 and CA16
neutralizing antibodies in seropositive individuals
To analyze the immunity level, the geometric mean titer
(GMT) of EV71 and CA16 neutralizing antibodies in
seropositive individuals was tested. The overall EV71
NA showed a moderate level, with GMT values of 51.6
(95% CI:40.6-64.5), 88.1 (95% CI:71.3-108.9) and 56.6
(95% CI:41.6-76.8) in 2007, 2008 and 2009 respectively
(Figure 2). For CA16, significant higher values were ob-
served than those for EV71 in each year tested (p < 0.05)
(Figure 2). The highest CA16 antibody level was identi-
fied in 2007, with a value of 175.5. Then the GMT values
gradually declined to 143.4 and 135.8 in 2008 and 2009
respectively (Figure 2).
GMT values of EV71 NA were slightly higher in 1–5
years group than in those 5 years older. The highest
GMT of EV71 in 2007 was in children aged 2 years
group (GMT 114.0). Then this value reduced across age
groups, fell to approximately 40.0 among those 5 years
or older (Figure 3A). Compared to 2007, the GMT in
2008 was relatively high in most of the age groups. Chil-
dren in 1–5 years groups had values no less than 87.7.
Then the immunity level decreased to 39.8 and 60.9 in
children aged 6–7 and 8–9. In 2009, the highest GMT
was identified in 1 year old children (GMT 128.0). Con-
trary to 2007, the 2 years group had a lowest value of 8
in 2009. Then this value gently increased with age, rising
from 39.0 to 101.6 in 3–5 year groups. Again, for those
aged more than 5 years, the GMT in seropositive indi-
viduals was relatively low. No one was found to be more
than 50.0. For CA16 (Figure 3B), the GMT values were
approximately equally distributed in 2007 and 2008.
Figure 1 Age-dependent seroprevalence of EV71 and/or CA16 antibody. Age-related seroprevalence of neutralizing antibodies to EV71 (A),
CA16 (B), or both of these two viruses (C) in individuals in Guangdong, China.













































































Figure 3 Geometric mean titer (GMT) of EV71 and CA16 antibody by age group. Age-related geometric mean titer (GMT) of EV71 (A) and CA16
(B) antibody in seropositive individuals. The lines indicate 95% confidence interval.
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Significant higher values were only observed in 2–3
years groups in 2007 and in 3 year group in 2008. While
in 2009, declining trend across age was identified, with a
sudden dip at age of 2 years.
Discussion
In humans, humoral immunity with neutralizing anti-
bodies played central roles in anti viral infection [35-37].
Recent vaccine studies in animal model also demon-
strated the protective effects of neutralizing antibody in
EV71 challenge [38,39]. In addition, surveillance data in
other countries also suggested a causative role for the
decreased herd immunity in susceptible population dur-
ing HFMD outbreaks [40]. To date, few surveillance data
were reported on seroepidemiology of EV71 and CA16
in China. In this study, the neutralizing antibodies
against EV71 and CA16 among children in Guangdong
were investigated. Seroprevalence changes before, during
and shortly after the national widespread epidemic in
2008 were described.
In China, HFMD was first reported in Shanghai in
1981, and since then, sporadic cases of HFMD in other
provinces including Beijing, Fujian, Shandong, Hubei,
Jilin were reported in 1980s. Recently the epidemic situ-
ation of HFMD in China tended to be more serious. In
2007, nearly 40,000 HFMD cases were reported in Shan-
dong and over 10,000 cases were recorded in large cities
such as Beijing and Shanghai [41]. However, little reports
have described the HFMD situations in Guangdong in
2007. Our results suggested moderate EV71 infections
occurred among the children in Guangdong before the
large HFMD epidemic in 2008. The overall seropreva-
lence of EV71 NA in 2007 was similar to those in 2005
in Guangdong, as well as those in 2006–2007 in Lu’an
[42,43]. About half of children less than 10 years old had
no neutralizing antibody against EV71. Compared to
EV71, significant higher positive rate of neutralizing
antibody against CA16 in 2007 was identified. This was
contrary to a previous study, which suggested more
common EV71 infections in South China in 2005 [42].
The high CA16 seroprevalence in 2007 indicated that
frequent asymptomatic and/or unrecognized CA16 in-
fections have occurred before and in this year. In 2008,
among 936 laboratory-confirmed cases, EV71 was found
in 59% and CA16 in 26% [19]. Considering the protect-
ive effects of neutralizing antibody in viral infection, the
epidemiology surveillance data in 2008, to some degree,
had verified our results. The seroprevalence of EV71 and
CA16 in this year could serve as HFMD trends predic-
tors for next year.
In March 2008, a serious HFMD epidemic with 20
deaths broke out in Fuyang City, Anhui Province, and
subsequently spread quickly in almost all provinces of
China [44]. After that, the Ministry of Health of China
classified HFMD as one of the category “C” notifiable
diseases. According to the Guangdong HFMD web-
based surveillance system, a total of 47,660 HFMD cases
were reported in 2008. And this number almost doubled
in 2009 (92,998 reported cases), was five-fold in 2010
(230,978 reported cases) [41]. To correlate the level of
immune protection to the incidence rate of HFMD
cases, seroprevalence of EV71 and CA16 NA in and
after the 2008 were also investigated. We didn’t find sig-
nificant higher positive rate of EV71 and CA16 in and
after 2008. Previous study suggested that HFMD pre-
sents a seasonal pattern every 2–3 years [45]. Together
with the increased incident rates of HFMD cases in
2009–2010, our results suggested that the peak of recent
HFMD epidemic cycle in Guangdong was not in year
2008 but in the years 2009 and 2010. Consistent with
these, Yu, et al. identified that children in Lu’an had sig-
nificant higher seropositive rate in 2010 when compared
to that before 2008 [43]. The ensuing HFMD epidemics
from 2008 to 2010 largely increased the exposed chance
of viral infection and thus the seropositive rate of viral
NA in children.
EV71 and CA16 were highly diverse in the nucleotide
sequences of structure proteins which serve as major
antigen in host immune response. Li et al. used VP1s
and VP4s as antigens to detect of serum antibodies
against EV71 and CA16 [46]. Their results suggested im-
munological reaction to VP1 and VP4 of both EV71 and
CA16 was different. The study from the clinical patient
also indicated that individuals with or without prior
EV71neutralizing antibody showed a similar incidence of
non-71 Enterovirus infection [47]. EV71 and CA16 were
the most common causes of HFMD diseases in recent
epidemics in China [44]. To evaluate the immune protec-
tion level against HFMD, we also calculated the propor-
tion of individuals that were positive for both the EV71
and CA16. In total, about 30.0% of all tested individuals
had antibodies both to EV71 and to CA16 before and
during the 2008 epidemic, while this rate greatly reduced
to 20.0% in year 2009. The large number of susceptible
individuals may be partly responsible for the large out-
break of HFMD in Guangdong in 2010. Similar with re-
ports in other countries, the dates in our study also
proved that individual susceptible probability depends on
the protective level of neutralizing antibodies. Epidemic
occurred when herd immunity decreased.
As a common febrile illness of early childhood, HFMD
occurred mainly among children ≤5 years old. In Guang-
dong, a total of 47,660 and 92,998 cases have been
reported to the provincial surveillance system in 2008
and 2009 respectively. The number of children ≤5 years
old accounted for the largest proportion (from 87.5% to
93.3%) [48]. These were highly consistent with the age
related seroprevalence trends in our study. In our
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results, both EV71 and CA16 NA rise with age among
children less than 5 years and reach a plateau thereafter
[34,49]. We also observed significant reduction at 2
years group, the most susceptible population that had
the highest incidence rates of HFMD in 2008 and 2009
epidemic year in Guangdong. In 2007, the lowest sero-
prevalence was identified in 1 year old children. While for
children in 2 year old group, slightly high positive rate was
shown. Epidemic waves before and in this year could not
be traced. Whether this different seroprevalence trend in
2007 provided an accurate picture, or it just was the result
of very small number of cases in 1 year group remains to
be determined by future investigations.
The GMT for EV71 and CA16 was also analyzed. All
the seropositive individuals in three years tested showed
relative high CA16 NA levels (Figure 2). Unlike a previ-
ous report conducted in Jiangsu province China, which
showed low antibody titers against CA16 in children
aged 2–15 years, the high GMT observed in this study
suggested common CA16 infections in Guangdong
province [27]. In addition, our data also suggested that
most of the EV71 infections are acquired when they
were less than 5 years old, while for CA16, mainly oc-
curred among 1–3 years groups (Figure 3), because the
highest antibody titers were observed in these age
groups and neutralizing antibody titers were high at
early stage of infection. GMT for both the EV71 and
CA16 were all declined among children 5 years or older,
which account for about 10% of the total reported
HFMD cases [48]. The relative low level of EV71 and
CA16 NA in these less susceptible populations indicated
a critical role for the long-lasting immunity rather than
immunity level in protecting against viral infection.
Conclusions
Altogether, the seroprevalence data in our study showed
a continuous circulation of EV71 and CA16 in Guang-
dong province China in 2007–2009. The relative high
seropositive rates in healthy children indicated many
clinically silent EV71/CA16 infections in these years.
These seropositive children that had asymptomatic or
unrecognized EV71/CA16 infection may serve as a res-
ervoir for continued viral spread in the population, and
should be taken into account when the government de-
velops and implements public health interventions. Con-
sistent with previous studies, age related increase of
seroprevalence was also identified in 1–5 years children
in Guangdong, which indicated common infections for
these age groups. And they should clearly be at the top
of the priority in periodical seroprevalence survey and
future vaccination campaign.
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